Vaxcyte, Inc. (PCVX)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Grant E. Pickering M.B.A.
|
Co-Founder, CEO & Director | 1.44M | 464.95k | 1968 |
|
Mr. Andrew L. Guggenhime M.B.A.
|
President & CFO | 960.23k | 1.33M | 1968 |
|
Mr. James T. Wassil M.B.A., M.S.
|
Executive VP, Chief Scientific Officer & COO | 614.73k | 1.87M | 1969 |
|
Mr. Harpreet S. Dhaliwal M.B.A.
|
Chief Technical Operations Officer | 743.62k | -- | 1973 |
|
Dr. Jeff Fairman Ph.D.
|
Co-Founder & VP of Research | -- | -- | 1964 |
|
Ms. Elvia Cowan
|
Senior VP of Finance & Chief Accounting Officer | -- | -- | 1973 |
|
Mr. Jeff Macdonald
|
Executive Director of Investor Relations | -- | -- | -- |
|
Mr. David McAvoy J.D.
|
Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | -- | -- | -- |
|
Ms. Whitney Jones
|
Chief People Officer | -- | -- | -- |
|
Ms. Janet Graesser
|
Senior Vice President of Corporate Affairs | -- | -- | -- |
Vaxcyte, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 507
Description
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Corporate Governance
Upcoming Events
November 3, 2026 at 8:00 PM UTC
Vaxcyte, Inc. Earnings Date
